Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
{{output}}
Introduction: The treatment of lung cancer is not defined in the third-line setting and remains an unanswered question. Erlotinib is the only drug approved in the third-line setting. With the introduction of effective first- and ... ...
